CYP19A1 and obesity due to melanocortin 4 receptor deficiency: A systematic review of three randomised controlled trials and five retrospective cohort studies suggested reduced efficacy of aromatase inhibitors in obesity, although the exact magnitude of this effect is not clearly established [136].